Autopsy report · NCT03132155

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

“Prematurely terminated due to lack of therapeutic effect”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months before it started.
• Ran for about 3 years 1 month before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 2 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

NantPharma, LLC

Sponsor type

Industry

Conditions

Clear Cell Sarcoma

Interventions

AMG 337

Participants

8

Sites

2

Countries

United States

Trials that died the same way

• Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
  “Terminated due to lack of efficacy” (80% match in meaning)
• An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
  “Terminated early due to a lack of efficacy.” (79% match in meaning)
• GSK2983559 First Time in Human Study
  “Terminated due to non clinical toxicology findings and reduced safety margins.” (74% match in meaning)
• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
  “Terminated due to unacceptable toxicity” (74% match in meaning)
• Comparing the Efficacy of Two Oral Rehydration Solutions, With or Without the Probiotic Lactobacillus Reuteri DSM 17938 and Zinc, on the Duration and Severity of Acute Gastroenteritis in 6 - 36 Months Old Children in Out-patient Care
  “Terminated due to lack of eligible patients.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.